Telix Pharmaceuticals (TLX) Goodwill & Intangibles (2023 - 2025)

Telix Pharmaceuticals (TLX) has reported Goodwill & Intangibles for 3 consecutive years, with $791.8 million the latest figure, recorded in Q4 2025.

• Quarterly Goodwill & Intangibles rose 169.43% year-over-year to $791.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $791.8 million (up 169.43% YoY) and the FY2025 annual result came in at $791.8 million, up 169.43% from the prior year.
• Goodwill & Intangibles grew to $791.8 million in Q4 2025 per TLX's latest filing, from $293.9 million in the prior quarter.
• Over the last five years, Goodwill & Intangibles for TLX reached as high as $791.8 million in Q4 2025 and fell as low as $77.4 million in Q4 2023.
• A 3-year average of $387.7 million and a median of $293.9 million in 2024 frame the typical range for Goodwill & Intangibles.
• Annual changes were most pronounced in 2024 — Goodwill & Intangibles jumped 279.47% — and 2025, when it surged 169.43%.
• Year by year, Goodwill & Intangibles stood at $77.4 million in 2023, then soared by 279.47% to $293.9 million in 2024, then jumped by 169.43% to $791.8 million in 2025.
• According to Business Quant data, Goodwill & Intangibles over the past three periods registered $791.8 million, $293.9 million, and $77.4 million for Q4 2025, Q4 2024, and Q4 2023 respectively.